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Islet transplantation is a promising therapy for type 1 diabetes mellitus; however, success rates in achieving both short- and long-
term insulin independence are not consistent, due in part to inconsistent islet quality and quantity caused by the complex nature
and multistep process of islet isolation and transplantation. Since the introduction of the Edmonton Protocol in 2000, more
attention has been placed on preserving mitochondrial function as increasing evidences suggest that impaired mitochondrial
integrity can adversely aﬀect clinical outcomes. Some recent studies have demonstrated that it is possible to achieve islet
cytoprotection by maintaining mitochondrial function and subsequently to improve islet transplantation outcomes. However, the
beneﬁts of mitoprotection in many cases are controversial and the underlying mechanisms are unclear. This article summarizes
the recent progress associated with mitochondrial cytoprotection in each step of the islet isolation and transplantation process,
as well as islet potency and viability assays based on the measurement of mitochondrial integrity. In addition, we brieﬂy discuss
immunosuppression side eﬀects on islet graft function and how transplant site selection aﬀects islet engraftment and clinical
outcomes.
1.Introduction
Since the introduction of the Edmonton Protocol in 2000
[1], human islet transplantation has emerged as a promising
therapy for type 1 diabetes mellitus (TIDM) and is the
only minimally invasive therapy able to achieve glycemic
control without exogenous insulin. As a cell therapy, islet
transplantation is a multistep process involving pancreas
organ procurement and preservation, tissue digestion and
dissociation, islet puriﬁcation, cell culture, islet transplanta-
tion via the hepatic portal vein of the recipient, and main-
tenance of the graft by nonsteroidal immunosuppressant
regiments. Successful islet transplantation is dictated by the
cumulative success of the aforementioned steps. To date,
islet transplantation has been shown to have variable success
in both short- and long-term insulin independence [2–5]
and much of this variability is associated with factors from
both the organ donor and recipient. In order to maximize
the success rate of achieving insulin independence, consid-
erable eﬀorts have been focused on the following aspects:
(i)developmentofasuitableorganpreservationsolution;(ii)
standardization of good manufacturing principles (GMP) in
islet isolation; (iii) development of an accurate potency test
that can predict islet graft function prior to transplantation
(as outlined by requirements for an FDA Biologics License);
(iv) development of a new immunosuppression regimen
with less islet graft toxicity; (v) improvement of islet graft
survival via ex vivo and in vivo manipulation; (vi) selection
of a more ideal transplant site.
While we often focus on getting more islets from
each islet isolation, one of the top priorities that should
not be neglected is the attainment of better quality islets
with preserved β-cell function and viability. Located in the
cytoplasm, the main function of the mitochondria is to
provide energy for the cell in the form of ATP. Cells use
this energy to perform the work necessary for cell survival
and function. Moreover, mitochondria are also involved
in other cell processes such as cell growth, division, and
apoptosis. Pancreatic islets consist of a cluster of 1000–2000
cells and ranging in size between 50–400μm in diameter.2 Biochemistry Research International
Composing 1-2% of the pancreas mass, each islet consists
of at least ﬁve diﬀerent cell types: α-cells (15–20% of
islet mass) producing glucagon; β-cells (65–80% of islet
mass) producing insulin and amylin; δ-cells (3–10% of islet
mass) producing somatostatin; PP cells (3–5% of islet mass)
producingpancreaticpolypeptide;ε-cells(<1%ofisletmass)
producing grhelin. Speciﬁcally for β-cells, mitochondria play
a key role in glucose-stimulated insulin secretion, not only
by providing energy in the form of ATP to support insulin
secretion, but also by synthesizing anapleurtoic metabolites
that can act, both intra- and extramitochondrially, as factors
that couple glucose sensing to insulin granule exocytosis.
ATP on its own, and possibly modulated by these anapleu-
rotic coupling factors, triggers closure of the ATP-sensitive
potassium channel, resulting in membrane depolarization
that increases intracellular calcium to cause insulin secretion
[6–9].
Recently, the roles of mitochondria in cytoprotective
applications involving ischemia-reperfusion (I/R) injury
have been acknowledged and continue to be actively inves-
tigated using chemical and physical means during both islet
isolation and on posttransplanted islet grafts. However, no
systematic review has been done in this respect. In this
review, we will examine current and past research from the
last ten years on the role of mitochondria and mitoprotective
strategies that have been applied in each phase of the islet
isolation process.
2. Mitochondria and Mitoprotectionin
Pancreas Organ Preservationand Storage
While initial results of human islet transplantation using
the Edmonton Protocol are promising, the need for a
large quantity of islets to achieve insulin independence
from multiple organs per patient creates an obstacle to the
application of human islet transplant as a routine clinical
procedure. Pancreas preservation and storage is the ﬁrst step
in the islet isolation process and has a critical impact on
islet yield and quality. During the isolation process, only a
fraction of the islets in a whole pancreas can be successfully
isolated with good function and viability; this is especially
t r u ef o ro r g a n sw i t hap r o l o n g e dc o l di s c h e m i at i m e .
Ischemia injury has been shown to signiﬁcantly decrease
the quantity and quality of islets that can be isolated from a
pancreas [10–12]. Hypoxia and ischemia, during the process
of pancreas procurement and storage, triggers a cascade
of cell signaling pathways that compromise islet viability
and function [13–15]. University of Wisconsin (UW) and
Histidine-Tryptophan-Ketoglutarate (HTK) solutions are
the two most commonly used organ preservation solutions
intended for islet isolation. Both are designed to protect the
organ from ischemia-related cell injury. As a gold standard,
UW solution is the ﬁrst solution thoughtfully designed for
use in organ transplantation and the ﬁrst intracellular-like
preservation medium. UW solution contains metabolically
inert substances (lactobionate, raﬃnose, and hydroxyethyl
starch) as a glucose substitute that maintains native osmotic
pressure,therebypreventingcellularedema.Inaddition,UW
solution also adds free radical scavengers along with steroids
and insulin. In contrast, the composition of HTK is similar
to that of the extracellular ﬂuid and is developed based on
theprincipleofdeactivatingandsuspendingofcellularorgan
function by withdrawal of extracellular sodium and calcium.
Together with intensive buﬀering of the extracellular space
by means of histidine/histidine hydrochloride, the period
during which organs will tolerate prolonged interruption
of oxygenated blood may be increased. However, both
solutions do not prevent the deleterious eﬀects of hypoxia
and ischemia per se, especially for prolonged cold storage of
the pancreas [16–18].
Enormous attempts have been made to reduce ischemia
injuries through the oxygenation of preservation solution.
Perﬂuorochemicals(PFCs)areoneofthechemicalsthathave
been developed so far with the most signiﬁcant impact on
islet isolation. The PFCs are cyclic or aliphatic hydrocarbon
molecules in which all the hydrogen atoms have been
replaced with ﬂuorine. PFCs are a good solvent for gases and
approximately40mLofoxygencanbedissolvedin100mLof
90–95% PFC solutions. This makes the compound attractive
as a vehicle to deliver oxygen and other gases in vivo and
in vitro. PFCs were ﬁrst induced by Kuroda et al. for whole
pancreas preservation in 1988 [19–21] as a two-layer storage
method (TLM) in combination with UW solution and later
adopted in pancreas preservation for islet isolation. Since
then, more than 50 research papers have been published in
both human and animal models and the impacts of PFCs on
islet isolation outcomes have been reviewed [22–27]. In the
following section, we will brieﬂy address the major ﬁndings
from these studies and discuss the possible reasons for the
observed discrepancy in success and failure for islet isolation
using PFCs and summarize these observations in Table 1,
along with additional oxygen carriers used for islet isolation.
In their early studies, Matsumoto and Kuroda showed
that when PFCs were used within the TLM protocol, they
demonstrated signiﬁcant increases in islet yield, function,
and viability. In addition, PFCs extended preservation times
[28–30] when compared against UW solution alone. The
T L Mw a st h e ni m m e d i a t e l ya n dw i d e l ya d o p t e de a r l yb ys e v -
eral renowned islet programs, which demonstrated similar
results [10, 31–33] and later adopted by others [34, 35]. One
study demonstrated that islets isolated using the TLM had
an improved energetic proﬁle with higher ATP content and
ATP/ADP ratio, as wells as 40% less peroxidative damage,
indicating the mitochondria as a likely target in a potential
mechanism [36]. In 2006, Ramachandran et al. analyzed
the expression of pro- and antiapoptotic genes in the islets
isolated using the TLM, which showed a signiﬁcant increase
intheexpressionofinhibitorofapoptosis(IAP)andsurvival;
accompanied by decreases in the expression of BAD, BAX,
and caspases (caspase-2, -8, and -9). The improved islet yield
by PFCs was linked to the inhibition of apoptosis mediated
by an undescribed mitochondrial pathway [37]. However,
more recently, several large-scale studies and a retrospective
meta-analysis indicated that the beneﬁcial eﬀect of the TLM
on islet isolation and clinical transplantation outcomes are
minimal as PFCs may only improve the preservation of
marginal organs [38–42]. Many contribute this ﬁnding toBiochemistry Research International 3
Table 1: Oxygen carriers used in pancreas organ preservation and islet isolation.
Oxygen carriers Beneﬁts Limitation References
PFC
(i) Prevention of ischemia injury
(ii) Improvement of islet yield and quality
(iii) Inhibition of apoptosis by mitochondrial
protection via oxygen loading
(iv) Preservation of islet cell energetic status
(v) Low islet oxidative stress
(vi) Better in vivo islet graft function
(i) Inconsistent results despite several large-scale
human trials
(ii) May only be useful for marginal donors with
prolonged ischemia
(iii) Limited oxygen penetration into pancreas
(iv) Poor water solubility
(v) Indeterminate biosafety
[22–42]
PFD (i) Preservation of islet ATP levels (i) Only tested in animal model
(ii) Impairment of insulin secretion [43]
poly SFH-P
(i) Improvement of islet yield and quality
(ii) Preservation of mitochondrial integrity
(iii) No increase in oxidative stress
(iv) Better in vivo islet graft function
(v) High oxygen tension with oxygen saturation
curve similar to RBCs
(i) Only in rodent model
(ii) Warm-ischemia model used may not be
applicable in a cold-ischemia model
(iii) Product discontinued
[44]
the poor capability of PFCs to promote oxygen penetration
into the whole pancreas as PFCs cannot be ﬂushed into
the pancreatic vascular system either with or without UW
solution due to its poor water solubility. In 2009, Matsumoto
et al. reanalyzed their previous data and contributed the
observed discrepancy to the lack of experience of organ
procurement teams [27] since a standardized protocol was
not widely accepted across all centers.
To date, there have been few other oxygen carriers that
have been tested for their eﬀects on pancreas preserva-
tion intended for islet isolation, mainly due to their low
oxygen carrier capability, poor water solubility, and poor
biocompatibility. In the pig pancreas model, oxygenated
perﬂuorodecalin (PFD) was used at various temperatures
showingthatpig pancreasoxygenationat20◦Cincreasesislet
ATP generation; however, the islets were found to have com-
promisedinsulinsecretioninresponsetoglucosestimulation
[43]. In a human islet study, F6H8S5, a newly developed
oxygen carrier composed of F6H8 (perﬂuorohexyloctane)
and silicone oil polydimethylsiloxane 5, was compared to
PFD,showing comparableresultslinking theoptimization of
ATP production during the cold storage period [44].
In a warm-ischemia rat model, oxygenated poly SFH-
P (polymerized and stroma-free hemoglobin-pyridoxalated)
was applied to the pancreas prior to enzyme digestion,
showing that the islets isolated from a poly SFH-P treated
pancreas had improved β-cell viability and mitochondrial
potential changes in response to glucose stimulation. In
addition, O2 delivery by the poly SFH-P did not increase
glutathione (GSH) levels (an indicator for oxidative stress)
or malondialdehyde (MDA) levels (an indicator for oxidative
injury) [45]. These results supported the notion that there
was a mitoprotective eﬀect associated with the Poly SFH-P
treatment. However, it is worth noting that other groups did
notfurtherconﬁrmthisstudyeitherinrodentorhumanislet
isolation process due to discontinuation of the product.
There have been multiple attempts to supplement UW
solution with other mitoprotective agents such as trophic
factors [46, 47], mitochondria-targeted antioxidant mito-
quinone [48], carvedilol (a non-selective β blocker/α-1
blocker) [49], epidermal growth factor (EGF), and insulin-
like growth factor-1 (IGF-1) [50, 51]. However, the beneﬁts
of these chemicals have not been veriﬁed by systematic
studiesorusedinpancreasorgansintendedforisletisolation.
Furthermore,aspeciﬁcproblemlinkedtopancreasorgan
preservation is the leakage of zymogens from the exocrine
pancreas. Within the pancreas, serine proteases exist in the
form of an inactive proenzymes and are secreted from the
pancreas as trypsinogen, chymotrypsinogen, and proelas-
tase. The activation pancreatic proteases during isolation has
been observed and found to be caused in part by crude
impurities in collagenase preparations [52]. The resulting
cell death during the isolation process releases immunogenic
intracellular proteases that prompt the generation of free
radicals in the mitochondria and trigger activation of
macrophages to produce proinﬂammatory cytokines. In
addition, Heiser et al. reported that there was a strong
increase in trypsin activity levels throughout the digestion
phase and that these increased levels correlated with poor
islet yields and function [53]. It has also been shown in
several studies that the addition of protease inhibitors, such
as Pefabloc and α1-antitrypsin (A1AT) in UW and HTK
solutions, as well as used as in the TLM, can increase islet
yield and function by eﬀectively inhibiting this uncontrolled
protease activity [32, 54–56]. However, a recent large-scale
study showed that Pefabloc actually did not improve the
overall islet yields. In addition, in one study, it was found in
that pancreas preserved in the TLM may provide even better
transplant quality islets in the absence of Pefabloc [57].
In summary, although some promising studies have
shown the beneﬁcial mitoprotective eﬀects for islets by
oxygenation and chemical addition to organ preservation
solutions, the involved underlying mechanisms and their
overall impacts remain controversial and grounds for further
study. In addition, since the introduction of the Edmonton
Protocol, islet yield from one pancreas remains low with
an average of 300,000–400,000 IEq depending on center
expertise. Organ preservation solutions such as UW or HTK
are still considered the most eﬀective solution for preventing
ischemic injury until other alternatives are available that4 Biochemistry Research International
speciﬁcally address the needs unique to pancreata intended
for islet transplant.
3. Mitochondria and Mitoprotectionin
Islet Isolationand Culture
Since reperfusion injury is one of the primary factors
associated with islet cell death during islet isolation, there
have been extensive investigations dedicated to minimizing
the eﬀects of reperfusion injury in order to improve islet
isolation outcomes. Reperfusion-related cell damage is due
inparttotheinﬂammatoryresponse ofislettissuesmediated
by the release of inﬂammatory factors including interleukins
and reactive oxygen species (ROS). Although the mechanism
is not fully characterized, both inﬂammatory factors and
ROS intertwine as either initiator or eﬀe c t o ri na ni n ﬂ a m -
matory cascade during islet isolation that may cause β-cell
dysfunction and death. During reperfusion and reoxygena-
tion, signiﬁcantly increased levels of ROS can degrade cell
and capillary membranes that cause additional release of
free radicals and act indirectly to initiate redox-signaling
pathways leading to apoptosis. In addition, reoxygenation
can restore ATP levels that may cause an increase in calcium
uptake by the mitochondria, resulting in massive calcium
overload and destruction of the mitochondria.
Oxidative stress has been shown to play a pivotal role in
cell injury during the islet isolation and transplantation pro-
cesses [106–108]; therefore, blocking oxidative stress should
have a beneﬁcial impact on transplantation outcomes. To
date, several antioxidants have been used to protect islet cells
fromoxidativeinjuryduringtheisolationandcultureperiod.
Herein, we will brieﬂy discuss these ﬁndings.
Bottino et al. demonstrated that activations of nuclear
factor-kappaB (NF-κB) and poly (ADP-ribose) polymerase
(PARP), two of the major pathways responsible for cel-
lular responses to stress, occur in islet cells during the
isolation procedure and precedes cellular dysfunction and
demiseincludingthedisruptionofmitochondrialmembrane
potentials (MMPs); mitochondrial permeability transition
pore (MPT) formation; and an intracellular increase of
accumulating ROS. NF-κB-dependent reactions, such as
the production and release of interleukins (IL-6 and IL-8)
and macrophage chemoattractant protein-1 (MCP-1), were
observed days after the isolation procedure. Proinﬂamma-
tory responses were even more pronounced when islets were
cultured under speciﬁc conditions which mimicked isolation
stress and correlated well with higher islet cell loss and
impaired secretory function [58]. In addition, Bottino et
al. showed that early interventions aimed at reducing β-
cell oxidative stress through the use of the catalytic antioxi-
dant probe AEOL10150 (manganese [III] 5,10,15,20-tetrakis
[1,3,-diethyl-2imidazoyl] manganese-porphyrin pentachlo-
ride [TDE-2,5-IP]) can eﬀectively reduce DNA binding of
NF-κB and the subsequent release of cytokines, chemokines,
and PARP activation in islet cells; thus resulting in higher
survivalandbetterinsulinreleasewhencomparedtocontrols
[58]. A similar study conducted by the same authors
demonstrated that the application of two SOD mimetics
(AEOL10113 and AEOL10150) can also protect human islets
from oxidative stress, showing a signiﬁcantly higher viable
islet mass and better in vivo islet graft function using a
marginal islet mass transplant model [59].
GSH (glutamate-glycine-cysteine) is one of the most
important nonenzymatic antioxidants available; however, it
is not cell permeable. Cells can synthesize GSH from its
precursors, such as glutamine. The importance of glutamine
for cell survival and proliferation in vitro was ﬁrst described
by Eagle et al. in 1956 [60]. The cytoprotective and anti-
apoptotic eﬀects of glutamine have been demonstrated in
intestinal epithelial cells by Evans et al. [61] and also in
pancreatic islets showing that GSH increases β-cell insulin
secretion [62–64]. In both human and rodent models,
intraductal delivery of glutamine into the pancreas prior
to digestion can increase GSH levels, reduce MDA levels,
and reduce the number of apoptotic cells. In addition to an
improved islet yield, the percentage of nude mice rendered
normoglycemic with glutamine-treated islets was higher
than the controls and time to reach normoglycemia was
decreased from average of 7.3 ± 3d a y st o1 .83 ± 0.4d a y s
[65, 66].
Although most antioxidant compounds have a wide
extracellular and intracellular distribution, they often fail
to accumulate within the mitochondria and require conju-
gation with lipophilic cations for mitochondrial targeting.
Their ability to enter the mitochondria and accumulate
within the matrix also depends on the inner mitochondrial
membrane potential (MMP) and its proton gradient; a
feature which may change depending on the metabolic
status of cells. This requirement may limit their capacity to
permeate depolarized cells. Moreover, the accumulation of
these antioxidant cations within the mitochondrial matrix
can lead to dissipation of inner MMP, an event that often
leads to cell death. As a result, these agents exhibit narrow
therapeutic dose ranges. To combat this, genetic strategies
are being explored to bolster the antioxidant defense of islets.
Ex vivo transfer of the manganese superoxide dismutase
(MnSOD) gene to mouse islets has extended islet graft
function in autoimmune diabetic mice. It has been observed
that the islets from mice that overexpress GSH peroxidase
and the two isoforms of SOD improve blood glucose control
in a marginal islet mass model.
A point of concern to its clinical application is that it
has been demonstrated that viral delivery systems can pose
potential oncogenic risks, compromise islet function, and
increaseimmunogenicity;thelatterbeingespeciallyconcern-
ing given the pathophysiological setting of T1DM. Recently,
two research groups have demonstrated that polyvalent
gold nanoparticles densely functionalized with covalently
immobilized DNA oligonucleotides (AuNP-DNA) have a
high penetrative capacity for islet cells which can reach the
islet cores of both mouse and human islets with no evidence
oftoxicity;demonstratingthatisletfunctionispreservedwell
both in vitro and in vivo as compared to control. One study
showed that AuNP-treated islets have normal mitochondrial
responsekineticswhenstimulatedbyglucose,inconjunction
with preserved calcium inﬂux and insulin secretion when
compared to control [109]. The other study indicated that
AuNP-DNA conjugated with antisense eGFP reduced eGFPBiochemistry Research International 5
expression in MIP-eGFP islets (mouse insulin promoter
controlledeGFP)[110]. AuNP and/or AuNP-conjugates may
represent a new generation of nucleic acid-based therapeutic
platforms aimed at improving islet engraftment, survival,
and long-term in vivo f u n c t i o n .I ti se x p e c t e dt h a tm o r e
investigations into the use of nanoparticles for cargo delivery
to islets will follow to conﬁrm this observation while
improving this functional delivery system.
In addition to using physical, chemical, and viral plat-
forms for delivery of antioxidative cargo, molecules that
have good penetrative ability have also been investigated.
SS-31(D-Arg-2 ,6 -dimethyltyrosine-Lys-Phe-NH2),ano v el
water-soluble antioxidant peptide, is one of a few molecules
tested that have demonstrated the ability to penetrate into
the core of islets and localize in the mitochondria [67]. In
addition, SS-31 preserves MMPs, reduces islet cell apoptosis,
increases islet cell yield, and improves posttransplantation
function as demonstrated by a prompt and sustained
normoglycemia; whereas untreated islet graft recipients
remained diabetic. One study has demonstrated that SS-31
can inhibit, with minimal cellular toxicity, mitochondrial
swelling, oxidative cell death, and I/R injury of cardiac and
neuronal cells [68]. However, to date there are no published
reports of the eﬀect of SS-31 in transplanted human islets.
The eﬀector mechanisms by which cytokines induce
β-cell death may also encompass both nitric oxide (NO)
dependent and independent pathways [69]. In rodent islets,
interleukin-1 beta (IL-1β) alone can induce iNOS expression
and the resultant NO production impairs β-cell function by
oxidation of mitochondrial aconitase (m-con) which leads
to diminished glucose oxidation and ATP production [70].
Steer et al. demonstrate that this NO-mediated pathway of
β-cell death is primarily necrosis mediated by the release of
the high-mobility group box 1 protein (HMGB1) [71]. In
contrast,humanisletsappeartobemoreresistanttocytokine
induced NO production and the primary mechanism of
dysfunctionmaybetheresultofmitochondrial ROSproduc-
tion and activation of proapoptotic caspase enzymes [72].
A variety of speciﬁc and nonspeciﬁc inhibitors of reactive
nitrogen and oxygen species have been evaluated for their
eﬀects on islets in culture and in vivo posttransplant. Inhi-
bition of iNOS by NG-monomethyl-L-arginine (NMMA)
or aminoguanidine (Pimagidine) in culture can block NO
production in both rodent and human islets [73]. Treatment
withN-acetylcysteineorglutathioneperoxidasecanenhance
the antioxidant capacity of islet β-cells [74, 75].
Whenhumanpancreaticisletsaretreatedwithacytokine
combination of IL-1β, tumor necrosis factor-alpha (TNF-
α), and interferon-gamma (IGN-γ) for 72h, a signiﬁcant
increase in the amount of cell death was observed by
TUNEL (terminal deoxynucleotidyl transferase dUTP end
labeling) and cell death detection [68]. Furthermore, this
study demonstrated that this cell death was associated with
apoptosis and mitochondrial swelling. A possible link has
been suggested between peripheral benzodiazepine receptors
(PBR), also known as translocator protein (TSPO), which
implicates a speciﬁc mitochondrial permeability transition
pore and tissue damage associated with the production of
inﬂammatory mediators.
Various vitamins (D3, E, Riboﬂavin, and C) have also
been used as antioxidants in vitro and in vivo and show
protective beneﬁts including increased insulin secretion,
higher islet cell viability, increased insulin gene expression,
and reduced lipid peroxidation. Since these results have been
reviewed previously [76], in this review we will not further
discuss the ﬁndings.
Recently, it has been hypothesized that a better strategy
couldbetoblocktheinitiationoftheinﬂammatorypathways
triggered by the interaction of IL-1β with its cellular receptor
(interleukin-1 receptor, IL-1R). The eﬀectiveness of the
IL-1R antagonist (Kineret, (Anakinra)) in blocking the
proapoptotic and necrotic eﬀects of exogenous IL-1β,T N F -
α,a n dI F N - γ on cultured rat islets has been investigated.
Anakinra is a U.S. FDA approved drug used as an anti-
inﬂammatory therapy in clinical trials of human subjects
with rheumatoid arthritis [77] and type 2 diabetes mellitus
(T2DM) [78]. It is a human recombinant, nonglycosylated
form of the human interleukin-1 receptor antagonist (IL-
1ra) consisting of 153 amino acids with a molecular weight
of 17.3kDa. The biologic activity of Anakinra derives from
competitive inhibition of IL-1β binding to the interleukin-
1 type I receptor (IL-1RI). In several animal models and
in vitro human islet studies, blocking IL-1β receptor (IL-
1R) has shown an eﬀective inhibition of activation of IL-
1β-dependent inﬂammatory pathways [79], enhancement of
islet engraftment [80] and islet graft function, and atten-
uation of amyloid polypeptide-induced proinﬂammatory
cytokine release [81]. All of these results support its feasible
application to human islets in vivo as a posttransplant
therapeutic regiment.
Two studies conducted by one group have demon-
strated the application of either pan-caspase inhibitor (N-
benzyloxycabonalyl-Val-Ala-Asp-ﬂuoromethyl ketone [Z-
VAD-FMK]) or more selective caspase inhibitor (EP1013
[zVD-FMK]) during postisolation culture and in vivo treat-
ment can reduce islet loss following prolonged culture and
reversediabetesfollowingimplantationofamarginalhuman
islet mass (80–90% reduction) into mice [82, 83]. Several
similarstudieshavealsodemonstratedthebeneﬁtsofcaspase
inhibitors for islet transplant [84, 111].
Some studies have demonstrated a signiﬁcant beneﬁcial
eﬀect of recombinant human prolactin (rhPRL) on β-cell
proliferation, islet secretion, cytoprotection, islet engraft-
ment, and function of the transplanted islets by revascular-
ization and β-cell survival [85–87]; however the underlying
mechanism is unclear. One recent study has shown that
cytoprotection may involve an increase in BCL2/BAX ratio
and inhibition of several caspases such as 8, 9, and 3 [88].
The signal transduction pathway of c-Jun NH2-terminal
kinase (JNK), a member of the stress-activated group of
mitogen-activated protein kinases (MAPKs), is preferentially
activated in response to islet isolation process, oxidative
stress,andcytokinetoxicity [89].Ithasbeenreportedthatan
IL-1β stormcausedbybraindeathsigniﬁcantlyactivatesJNK
and reduces islet yield, viability, and function both in vitro
and in vivo after transplantation [90]. It has also been shown
that islet injection into the hepatic portal vein system leads
t oas t r o n ga c t i v a t i o no fJ N K[ 91]. The application of JNK6 Biochemistry Research International
inhibitorduringisletcultureandtransplantationcanprevent
islet loss and in vivo graft function [91, 92]. In addition,
a JNK inhibitor has also been also added to pancreas
preservation solution showing a strong inhibition of JNK
which prevented apoptosis immediately after isolation [93].
Previously, we discussed that the activation of trypsin
and other endogenous pancreatic zymogens contribute to
decreased islet yields via the uncontrolled proteolysis of col-
lagenase and the prolongation of digestion times. Attempts
to use Pefabloc during the isolation process instead of
organ preservation phase have been made, showing that the
Pefabloc can inhibit serine protease activity throughout the
tissue digestion process; but, with controversial results on
islet yield and function [94–96]. In addition, two research
papers recently published by the same group show that
when human islets were cultured or perifused with Pefabloc
postisolation, insulin secretion of human islets in response
to glucose stimulation was compromised, suggesting that the
Pefabloc is not suitable for human islet isolation [97, 98].
Summarized in Table 2, are the major antioxidative and
anti-inﬂammatory chemicals used in pancreas preservation,
islet isolation, and islet culture.
4. Evaluation of Mitochondrial Integrity for
HumanIsletFunction andViabilityAssays
The U.S. Food and Drug Administration (FDA) deﬁnes
the preparation of the islet product as a biological drug;
therefore, islet products for transplant need to be prepared
under FDA-approved guidance before islet transplant can
be approved as a clinical therapy. Despite standardization
and application of current good manufacturing practices
(cGMPs) in the islet isolation process, lot-to-lot variability
still cannot be avoided. To reduce the risk of transplanting
low-quality islets, appropriate product release tests are
needed. While tests for sterility, identity, and purity are well
established, so far no reliable assessment of islet potency is
available prior to transplant. This continues to be one of the
key variables associated with clinical transplant outcomes.
The existing standard assays used to assess islet func-
tion and viability include static glucose-stimulated insulin
stimulation (GSIS) for potency, and inclusive and exclusive
dyes to stain membrane integrity for viability. Both of
these techniques have low predictive values and do not
correlate well with clinical transplant outcomes [112–116].
Presently, clinicians determine the suitability of a given islet
preparation mainly based on both subjective measurements
(e.g., morphology) and islet cell mass (IEq, a volumetric
quantiﬁcation of islet mass). The underlying reasons for
the poor predictive value of GSIS are less clear; however,
there are several possible explanations. Static GSIS only
measures “bulk” insulin release from an islet preparation
under extreme conditions (16.7mM and 60min glucose
exposure), completely ignoring the dynamic physiological
nature of β-cell insulin secretory kinetics in response to
glucose.Inaddition,the“bulk”insulindatadoesnotprovide
any useful information of the key stimulus-coupling factors
that are necessary for controlling and regulating both insulin
secretion and viability in vivo. For example, mild stress
during pancreas preservation and islet isolation process can
lead to temporary insulin degranulation and leakage caused
by cell membrane damage, even though the islets are still
viable. Therefore, a low GSIS may not indicate irreversible
loss of function, as the temporarily impaired islet cells may
recover when transplanted into a recipient. Likewise, a high
GSIS result may be caused by insulin degranulation via cell
membrane damage.
Islet size is another factor that can cause variable GSIS
results. Unlike in situ, the isolated islet’s sensing of ambient
glucose changes is totally dependent on the passive diﬀusion
of glucose [99, 114]. Since smaller islets have a larger surface
area, a better GSIS would be expected [100, 117]i na
population of smaller islets. In clinical practice, IEq is used
as a determining factor in deciding the suitability of a given
islet preparation when human islet potency is less deﬁned or
hard to quantify. It is a general consensus that, in order to
reverse diabetes in type 1 diabetes recipients, at least 5,000
IEq per kilogram of recipient body weight are needed for one
transplant. Paradoxically, larger size islets contribute more
IEq but release less insulin which is a likely explanation
of why islet graft success does not correlate strongly with
transplanted islet mass.
On the contrary, the in vivo potency assay which
evaluates islets by transplanting human islets into immun-
odeﬁcient nude mice correlates extremely well with clinical
transplant outcomes and is currently the gold standard for
evaluating islet potency. However, this in vivo analysis takes
several weeks to complete and, therefore, only provides a
retrospective indication of islet function that renders this
assay impractical as a pretransplant assessment in the time
critical clinical setting [101, 103, 118, 119].
To address this problem, a variety of in vitro tests have
been investigated and developed in order to assess islet
potency and viability prior to islet release for transplant,
including: measuring the oxygen consumption rate (OCR)
[104, 114, 115, 120, 121]; the quantiﬁcation of reactive
oxygen species (ROS) [116]; and ADP/ATP ratios [105, 122].
Inadditiontobeingretrospectivelyusefulandlesspredictive,
these assays have multiple limitations. To begin with, most
OCR and ROS assays are conducted statically as a single
parameter. Additionally, OCR and ROS assays are less β-
cell speciﬁc, as an islet has at least ﬁve diﬀerent cell types
and β-cells only make up 65–80% of a human islet cell
population. Without a weighted analysis of ROS for each
individual cell group, this information is confounded; and
even then the measurements may be artefactual as islets
are one physiologic and metabolic functional unit. Recently,
more and more evidence has demonstrated that chemical
and/or ion communication among β-cells or between β-
cells and α-cells is important for the regulation of insulin
secretion [123, 124]. In addition, gap junctional complexes
between adjacent islet cells are also needed to facilitate
intraislet cell-cell communications and coordination for
hormonal output [102]. Therefore, others often challenge
the accuracy of ADP/ATP assay since the assay requires
islet dissociation. A comprehensive review on these assays
has been recently published [113]. Herein, we will brieﬂyBiochemistry Research International 7
Table 2: Major anti-oxidative and anti-inﬂammatory chemicals used in pancreas preservation, islet isolation, and islet culture.
Chemicals Beneﬁts Limitation References
AEOL10150
AEOL10113
(i) Antioxidative (SOS mimics) used in both
isolation stage and culture
(ii) Reduction of NF-κB binding of DNA
(iii) ↓IL-6,8; ↓MCP-1
(iv) Inhibition of the release of cytokines and
chemokines and PARP activation
(v) Protection of islets from oxidative stress
(i) No in vivo islet graft function available
(ii) Has not been demonstrated by other
groups
[58, 59]
Glutamine
(i) Beneﬁts in both animal and human models
during islet isolation
(ii) Increasing of GSH levels
(iii) Reduction of malondialdehyde and
apoptotic cells
(iv) Improvement of in vivo islet graft function
(i) Needs to be demonstrated by large-scale or
multicenter studies
(ii) Short-term eﬀect due to instability and
short half-life of glutamine
(iii) Relationship with inﬂammatory cascade
needs to be tested
[60–66]
SS-31
(i) Water-soluble antioxidative peptide with
high islet penetration
(ii) Speciﬁc mitochondrial targeting
(iii) Preservation of mitochondrial polarization
and reduced apoptosis
(iv) Improvement of islet in vivo function
(i) Needs to be demonstrated by large-scale or
multicenter studies
(ii) Only tested in animal model
[67, 68]
NMMA Aminoguanidine
N-acetyl cysteine
Glutathione peroxidase
(i) Blockage of NO production via inhibition
of iNOS in rodent and human islets
(ii) Enhancement of islet antioxidant capability
(i) Only demonstrated in vitro
(ii) The beneﬁts for islet transplant need to be
shown
[69–75]
Vitamins (D3, E,
Riboﬂavin, C)
(i) Increased insulin secretion
(ii) Higher islet viability
(iii) Increased insulin gene expression
(iv) Decreased lipid peroxidation
(i) Application in human islet isolation is
limited
(ii) No documented beneﬁts on human islet
receipts
[76]
Anakinra
(i) IL-1R antagonist via competitive inhibition
(ii) ↓TNF-α; ↓IL-1β; ↓IFN-γ
(iii) FDA approved as anti-inﬂammatory agent
(i) Not demonstrated in human islet isolation
and transplant [77–81]
Pan-caspase (ZVAD-FMK)
and selective caspase
inhibitor (zVD-FMK)
(i) Reduced islet loss during culture
(ii) Improve islet graft function
(iii) Reduced islet cell apoptosis
(i) No demonstrated beneﬁts in human islet
receipts [82–84]
Prolactin
(i) Increased β-cell proliferation
(ii) Increased insulin secretion
(iii) Cytoprotection
(iv) Improved islet engraftment
(v) Increased islet revascularization
(vi) Increased BCL2/BAX ratio
(vii) Inhibition of caspase 8, 9 and 3
(i) Less understanding of mechanism
(ii) Needs to be demonstrated by large-scale or
multicenter studies
[85–88]
JNK inhibitor
(i) Increased islet yield
(ii) Improved islet viability
(iii) Improved in vivo graft function
(i) Limited information on human patients
(ii) Large-scale study need to conﬁrm [89–93]
Pefabloc
(i) Eﬃcient inhibition of serine protease
activity
(ii) Has been applied in all phases of isolation
(iii) No interference with collagenase activity
(i) Controversial results on islet yield
(ii) Inhibited insulin secretion in vitro [94–98]
discuss the assays measuring mitochondrial integrity for
islet potency and viability. In Table 3, we summarized the
strengths and limitations of these assays.
In the search for a more reliable and β-cell speciﬁc
potency assay, the measurement of mitochondrial integrity
has been emerging as an alternative assay in the form of a
single parameter or combined with other parameters for islet
viability and potency.
Zinc is highly concentrated in β-cells but much less
concentratedinotherisletcelltypes.Zincplaysanimportant
role in the packaging insulin granules as it is ﬁrmly
established as an integral coordinating atom of the insulin
crystal as a 2-Zn-insulin hexamer. Recently, Newport Green
(NP), a less-toxic zinc-sensitive ﬂuorescent probe, has been
used for the identiﬁcation and puriﬁcation of human β-
cells [125]. In 2005, Itchii et al. reported a novel combined
analytical method in which β-cells were ﬁrst speciﬁcally
identiﬁed using NP labeling and sorted by laser scanning
cytometry (LSC). NP+ positive cells were then evaluated for
viability using TMRE (tetramethylrhodamine ethyl ester),8 Biochemistry Research International
Table 3: Advantages and disadvantages of mitochondria-based islet potency and viability assays.
Assays Advantages Disadvantages References
Newport Green +
TMRE
(i) Low toxicity of Newport Green Dye
(ii) β-cell speciﬁc
(iii) Correlates with in vivo islet function
(i) Islet dissociation needed
(ii) Nonstimulated static assay
(iii) Complex instrumentation and setup required
(iv) Diﬃcult to quantify MMP
(v) Not real time
[99, 100]
FluoZin-3 +
TMRE
(i) β-cell speciﬁc
(ii) FluoZin-3 has higher aﬃnity (KD= 15nM) for
Zinc and higher quantum yield
(i) No correlation has been demonstrated with in
vitro and in vivo islet function
(ii) Nonstimulated static assay
(iii) Complex equipment requirement and setup
(iv) Diﬃcult to quantify MMP
(v) Not real time
[101, 102]
JC-1 + ROS
(i) Multiparametric assay
(ii) Strong correlation of MMP with ROS
(iii) Dynamic ROS assay
(iv) Correlate with in vivo function
(i) Non β-cell speciﬁc
(ii) Non-stimulated static assay of MMP
(iii) Procedure complexity
(iv) Intact islet assay for ROS but need islet
dissociation for MMP
(v) Not real time
[88, 103]
Multiparametric
microﬂuidic assay
(Rh123 +
Fura-2AM +
insulin kinetics)
(i) Multiparametric assay of key
stimulus-secretion coupling factors (MMP:
Rh123, Ca2+: Fura-2AM; Insulin: ELISA)
(ii) Dynamic response to stimulator
(iii) Intact islets
(iv) Real time
(v) High throughput
(i) Large-scale evaluation needed
(ii) Moderate spatiotemporal resolution of the
measured parameters
[104, 105]
a mitochondrial membrane potential ﬂuorescence probe
[126]. The data presented in the study strongly suggest that
analysis of β-cell viability by TMRE is of critical value for the
prediction of transplant outcomes in the immunodeﬁcient
mouse model. Furthermore, the study ﬁnds that DNA-
binding viability exclusion dyes do not always correlate
with in vivo graft function; a strong argument suggesting
the inadequacy of inclusion/exclusion dyes as a predictive
assay of long-term islet viability. These ﬁndings are further
conﬁrmed by other studies [127]. In addition, TMRE used
in conjunction with FluoZin-3, another zinc-speciﬁc probe
but with a higher aﬃnity (KD = 15nM) and higher quantum
yield, can also be used to assess β-cell viability using ﬂow
cytometry. The functionality of β-cells is determined by the
retention of the MMP indicator in conjunction with TMRE
in FluoZin-3+ β-cells [128, 129]. In other studies, the MMP
measured by the mitochondrial JC-1 ﬂuorescence probe are
used in parallel to correlate changes in luminol-measured
ROS, showing a decrease in the percentage of cells with
normal mitochondrial polarity with a low responsive index
in both glucose- and rotenone-stimulated islets. Regression
analysis shows the rotenone stimulation index is signiﬁcantly
correlated with the percentage of islet cells with polarized
mitochondria [116, 130].
While these results are promising, the aforementioned
assessments of mitochondrial integrity measurea static value
of β-cell energetic status with only retrospective values since
these assays may take days to conduct and cannot predict
islet graft function at the time of transplant. In addition,
as an enzymatic dissociation of the islets is involved, the
assays’ methodology is often questioned for introduction of
artefacts, such as selective damage or and loss of to the β-
cell population. Furthermore, most of these assays require
moresophisticatedlaboratorysetups,suchasFACS,confocal
microscope, and laser scanning cytometry. However, these
ﬁndings strongly suggest that a testing method that has the
capability of measuring dynamic changes in mitochondrial
potential kinetics in whole islets in response to insulin
secretagogues (such as glucose), in parallel with other assays
that measure key insulin stimulus-secretion coupling factors,
would be useful in determining islet function prior to
transplantation. In order to achieve this type of a test, it is
necessary to use microﬂuidic technology.
Microﬂuidic technology has been used for a wide range
of analytical applications and recently these techniques
have been adopted to develop versions of islet perfusion
apparatuses,integratedwitheithersingleormultipleanalysis
tools for islet and β-cell studies [131–133]. Microﬂuidic
technology has a number of advantages over conventional
techniquesinthatsmalleramountsofreagentandbioanalyte
are required, it is simple to create and maintain an exper-
imental microenvironment, and microﬂuidic assessment
allows for the easy integration of analytical tools such
as optical and electrical assays. In addition, the fabrica-
tion techniques are favorable for portability and economic
mass production of highly elaborate devices. Recently, a
microﬂuidic-based perfusion setup has been developed
for the simultaneous imaging of mitochondrial potentials
changes and calcium inﬂux as well as insulin release kinetics
of whole islets in response to glucose stimulation [134, 135].
This mitochondria-based islet assay is associated with the
following features: (i) multiparametric assay of key insulinBiochemistry Research International 9
stimulus-secretion coupling factors including intracellular
calcium signaling, mitochondrial potentials changes, and
insulin secretion kinetics; (ii) real-time whole islet assay with
no islet ﬁxing or dissociation is needed; (iii) β-cell speciﬁc
sinceisletsareevaluatedinresponsetostimulationbyinsulin
stimulators; (iv) suﬃcient spatiotemporal resolution of all
measured parameters. Although the system shows promising
results, a large-scale evaluation of human islet products is
needed in conjunction with data correlating results to in
vivo graft function in both animal and human models. This
work is currently under way following a clinical trial and
is expected to validate a mathematical model for an islet
functional index (IFI) score.
In spite of various assays available, a conclusive potency
test still needs to be developed and veriﬁed for universal
acceptance by the islet transplant community. Ideally, this
potency test needs to be real-time, β-cell-speciﬁc, sensitive,
reliable, robust, and have practical applicability.
5. Impact of Mitochondria on
Selection of Immunosuppression
Regiment and TransplantSite
Besides the infusion of a suﬃcient number of high-quality
islets and careful recipient selection of patients with normal
kidney function and low insulin requirements, another
important factor for the success of the Edmonton Protocol
is the development of a new steroid-free immunosuppressive
therapy in combination of sirolimus (rapamycin, an mTOR
inhibitor) and low dose of tacrolimus (FK506, a calcineurin
inhibitor), and induction with daclizumab (an anti-IL2-
receptor monoclonal antibody).
It has been suggested in the past that posttransplant
islet graft failures can be caused by several reasons including
initial failure of islet engraftment, inﬂammatory response at
the transplant site, alloreactive (rejection) or autoimmune
response, and immunosuppressive drug-induced β-cell toxi-
city [136]. Although their long-term side eﬀects are still not
fully known, immediate side eﬀects of immunosuppressive
drugs include mouth sores, gastrointestinal disturbance
(stomach upset and diarrhea), high cholesterol levels, hyper-
tension, anemia, fatigue, decreased white blood cell counts,
decreased kidney function, and increased susceptibility to
bacterial and viral infections. Taking immunosuppressive
drugs also increases the risk of tumors and cancer. Several
studies have systemically reviewed each of these aspects;
this review will only brieﬂy address a few of the ﬁndings
of the eﬀects of immunosuppressants in relation to islet
mitochondrial-based cytoprotection.
Although extensive studies have investigated the eﬀects
of sirolimus and tacrolimus on islets in vitro and in vivo,
as well as in the islet transplant patients, conﬂicting results
have been reported. Sirolimus inhibits the mTOR (the mam-
malian target of rapamycin) pathway by directly binding
mTOR Complex 1 (mTORC1). It has been shown that the
mTOR signaling pathway integrates both intracellular and
extracellular signals and serves as a central regulator of
cell metabolism, growth, proliferation, and survival. It has
also been demonstrated that mitochondrial metabolism and
biogenesis are both regulated by mTORC1. Through the
inhibition of mTORC1, sirolimus lowers MMP, oxygen con-
sumption, and ATP levels. In addition, it reduces mitochon-
drial DNA copy number and many genes encoding proteins
involved in oxidative metabolism [137, 138]. The mTOR
signaling pathway also prevents islet cells from initiating
authophagy [139]. Therefore, the inhibition of mTORC1
by sirolimus causes downregulation of T-lymphocytes while
promoting authophagy and increasing the probability of
initiating apoptosis. This has been demonstrated in a
mouse model, whereby treatment with sirolimus induced
an increase in membrane-bound light chain 3 (LC3-II), an
early marker of authophagy, as well as a decrease in cell
viability. In this experiment, sirolimus-mediated activation
of authophagy was shown to be rescued by treatment with
3-methyladenine (3-MA), an inhibitor of authophagy [140].
Since sirolimus monotherapy is not suﬃcient to suppress
islet graft rejection, it is often used with other immunosup-
pressants. Tacrolimus is one of the most commonly used
immunosuppressant agents often used in combination with
sirolimus. Tacrolimus immunosuppression blocks antigen-
stimulated expression of genes such as IL-2 in T-cells, which
is required for T-cell proliferation. It is generally assumed
that the mechanisms involved in tacrolimus toxicity are
similar to those of cyclosporine (CsA) by inhibition of
mitochondrial ATP production and disruption of mito-
chondrial ion channels. However, some researchers have
suggested that in an I/R model, tacrolimus protects neural
tissues from adverse conditions such as overaccumulation
of calcium, oxidative stress, cytochrome c release, and BAD
phosphorylation [141, 142].
In clinical practice, sirolimus has been shown to increase
basal and stimulated insulin secretion when maintained
within a plasma-drug concentration target with reduced
β-cell apoptosis [143]. When cultured with human islets,
sirolimus decreases TNF-α,I L - 1 β, MCP-1, and macrophage
inﬂammatory protein-1beta (MIP-1β) from impure islet
preparations [144]. In the patients receiving sirolimus as
preconditioning for islet transplant, an increase in fasting
C-peptide levels and a decreased insulin requirement were
observed [145]. In an in vivo rodent model, islet graft
function was preserved in association with a pretransplant
reduction in chemokines CCL2 and a dampened chemokine
response posttransplant [146]. However, conﬂicting results
have also been reported. Sirolimus has been found to impair
metabolism secretion coupling by suppressing carbohydrate
metabolism resulting in lower ATP levels, a slower glucose
oxidation rate, and inhibited alpha-ketoglutarate dehydro-
genase (AKGDH) [147]. In addition, sirolimus has been
associated with a reduction in the amount of vascular
endothelial grow factor (VEGF) that is released by the islets;
a reduction in islet viability by blocking the VEGF-mediated
survival pathways [148], as well as reduction in glucose-
induced insulin secretion in vivo [149].
The detrimental eﬀects of tacrolimus on β-cell func-
tion have been well documented including a reduction of
insulin granules; decrease in insulin release; inhibition of
insulin transcription as determined by RT-qPCR of insulin10 Biochemistry Research International
mRNA levels; reduction of glucokinase (I-GLK, hexokinase-
4) activity using cell lines, rodent islets, and human islets
[150–154]. One study has shown that tacrolimus reduces
mitochondrial density and oxygen consumption at a phar-
macologically relevant concentration without changes in
either the rate of ATP production nor apoptosis. Microarray
dataindicatethattacrolimusmodiﬁesthepathwaysinvolving
ATP metabolism, membrane traﬃcking, and cytoskeleton
remodeling, indicating that tacrolimus causes mitochondrial
dysfunction at the level of gene transcription and translation
that causes a reduction in mitochondrial contents and
respiration [155]. In 2009, one study compared the eﬀect on
sirolimus, tacrolimus, and mycophenolate mofetil (MMF)
on glucose-induced insulin secretion in human islets and
found out that all three of the drugs tested increased
caspase-3 cleavage and caspase-3 activity. Tacrolimus has
been shown to have acute and direct eﬀects on insulin
exocytosis, whereas MMF does not but still has impaired
insulin secretion suggesting indirect eﬀects on insulin exocy-
tosis. Interestingly, exenatide (exendin-4), a GLP-1 agonist,
can ameliorate impairments in insulin secretion caused by
sirolimus, tacrolimus, and MMF [156].
In an in vivo rat model, sirolimus has been used with
cyclosporine,showingthatthecombinedtreatmentincreases
blood glucose and HbA1c levels, as well as the HOMA-R
[fasting insulin (mU/mL) × fasting glucose (mmol/L)/22.5]
index. When CsA was withdrawn, in vivo islet graft function
was compromised when the patient was maintained with
sirolimus [157]. One clinical case study reported that a
patientwhopresentedwithsirolimustoxicityintolerancewas
convertedtoMMFwithlow-dosetacrolimusandmaintained
with a monthly infusion of daclizumab, showed good long-
term islet graft function and improved renal function [158].
While a body of evidence seems to support the notion
that most immunosuppressants currently used for islet
transplant have at least some level of toxicity on islets and
aﬀect islet graft function, some conﬂicting results have been
reported.Manycontributetheseincongruentobservationsto
the selection of experimental models: in vivo versus in vitro,
short-term versus long-term, cell line versus primary cells,
animal versus human, and dosage diﬀerence.
Inadditiontoimmunosuppressanttoxicity,themicroen-
vironment of the islet engraftment site within the hepatic
portal vein system has also been suggested as one of the main
contributing factors associated with the loss of islet mass and
function posttransplant. Within moments of islet implanta-
tion, a cascade of nonspeciﬁc inﬂammatory events known
as instant blood mediated inﬂammatory reaction (IBMIR)
are initiated which include activation of blood-mediated
coagulation pathways [159] and release of proinﬂammatory
cytokines (PIC) primarily from macrophage, Kupﬀer cells,
andendothelialcells.Ithasalsobeensuggestedthatcytokines
producedbytheimmunesystemposttransplantcaninﬁltrate
pancreatic islets and serve as mediators of β-cell destruc-
tion [136]; as well as higher levels of immusuppressants
that are directly toxic or damaging to the transplanted
islets. The physical and chemical microenvironments of the
hepatic portal system are also considered suboptimal for
islet engraftment and survival: low oxygen tension and a
high concentration of waste and nutrients may cause islet
glucotoxicity and lipotoxicity. When islets are exposed to
chronic hyperglycemic and hyperlipidemic environments,
their overall function can be compromised including loss
of glucose sensitivity, β-cell exhaustion, and glucotoxic-
ity/lipotoxicity [160, 161]. Glucotoxicity and lipotoxicity are
closely interrelated and complementary for their deleterious
eﬀects on β-cell function. Glucotoxicity involves several
transcription factors and is in part mediated by chronic
mitochondrial reactivespeciesgenerationandaccumulation.
Lipotoxicity is probably mediated by the accumulation of
a cytosolic signal derived from the fatty acid esteriﬁcation
pathway. Very few studies have been published that investi-
gate islet grafts in the hepatic portal system due to the lack
of good in vitro and in vivo models that can closely mimic
this islet graft microenvironment. New alternative sites are
currently being investigated including intramuscular, bone
marrow, and the peritoneal cavity that could potentially
decrease the stress to islets. While this topic is important
for improving islet transplantation outcomes it has been
previously reviewed in several other papers in greater depth
[162, 163].
6. Summary
Recently, improvements in islet isolation techniques and
the selection of optimal immunosuppression regiments have
made human islet transplantation a viable clinical avenue
in the treatment for T1DM patients. Inconsistent success
rates are observed between short-term and long-term graft
survival among centers and this could be related to the use
of islet products of less than optimal quality and quantity.
Mitochondrial functions are potentially compromised in
each step of islet isolation and transplant process and
subsequently can negatively inﬂuence islet engraftment and
survival. The evidence presented in this review supports
the following hypotheses: (i) mitochondrial dysfunction is a
mediator for the onset and progression of islet I/R injury;
(ii) potential therapeutics targeting mitochondrial processes,
including energy metabolism, cytokine-induced inﬂamma-
tory reaction, and free radical generation, will be promising
in preserving islet function and viability. However, to con-
ﬁrm the role of mitochondrial cytoprotection in the isolated
islets for transplant, it will be necessary to demonstrate
these results in appropriate animal models and in a large
cohort study of islet isolation by multiple centers to correlate
clinical transplant outcomes. In addition, it is important
to correlate a more sensitive and reliable islet viability and
potency assay based on the evaluation of mitochondrial
integrity in conjunction with other parameters to prevent
the transplantation of a low quality islet preparations. Future
eﬀorts are also needed to better understand the underlying
mechanisms of immunosuppressant-mediated islet toxicity
and to discover a new generation of immunosuppressants
that are less damaging to islets. Lastly, it is important to
improve the islet transplantation process by decreasing islet
loss potentially by ﬁnding a more suitable transplantation
site in order to achieve consistent transplantation outcomes.Biochemistry Research International 11
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